| Literature DB >> 35464468 |
Sonia Villanueva-Hernández1, Mahsa Adib Razavi1, Katinka A van Dongen1, Maria Stadler2, Karelle de Luca3, Niklas Beyersdorf4, Armin Saalmüller2, Wilhelm Gerner1,2, Kerstin H Mair1,2.
Abstract
Antibody-secreting plasma cells (PCs) have remained largely uncharacterized for years in the field of porcine immunology. For an in-depth study of porcine PCs, we identified cross-reactive antibodies against three key transcription factors: PR domain zinc finger protein-1 (Blimp-1), interferon regulatory factor 4 (IRF4), and paired box 5 (Pax5). A distinct Blimp-1+IRF4+ cell population was found in cells isolated from blood, spleen, lymph nodes, bone marrow, and lung of healthy pigs. These cells showed a downregulation of Pax5 compared to other B cells. Within Blimp-1+IRF4+ B cells, IgM-, IgG-, and IgA-expressing cells were identified and immunoglobulin-class distribution was clearly different between the anatomical locations, with IgA+ PCs dominating in lung tissue and IgM+ PCs dominating in the spleen. Expression patterns of Ki-67, MHC-II, CD9, and CD28 were investigated in the different organs. A high expression of Ki-67 was observed in blood, suggesting a plasmablast stage. Blimp-1+IRF4+ cells showed an overall lower expression of MHC-II compared to regular B cells, confirming a progressive loss in B-cell differentiation toward the PC stage. CD28 showed slightly elevated expression levels in Blimp-1+IRF4+ cells in most organs, a phenotype that is also described for PCs in mice and humans. This was not seen for CD9. We further developed a FACS-sorting strategy for live porcine PCs for functional assays. CD3-CD16-CD172a- sorted cells with a CD49dhighFSC-Ahigh phenotype contained Blimp-1+IRF4+ cells and were capable of spontaneous IgG production, thus confirming PC identity. These results reveal fundamental phenotypes of porcine PCs and will facilitate the study of this specific B-cell subset in the future.Entities:
Keywords: BLIMP-1; IRF4; immunoglobulin classes; pig; plasma cells
Mesh:
Substances:
Year: 2022 PMID: 35464468 PMCID: PMC9024106 DOI: 10.3389/fimmu.2022.854257
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Primers for target gene amplification.
| Target gene | NCBI accession number | Primer sequence 5′ to 3′ forward (F) and reverse (R) | Position 5′ | PCR product length (bp) | Restriction overhang |
|---|---|---|---|---|---|
|
| XM_005659340 | F: | 803 | 1516 | EcoRI |
| R: | 2306 | XhoI | |||
|
| NM_001253352 | F: | 7 | 1415 | EcoRI |
| R: | 1409 | XhoI | |||
|
| XM_003122019 | F: | 247 | 1362 | EcoRI |
| R: | 1596 | XhoI |
Primers were designed using the NCBI primer BLAST tool (45). EcoRI and XhoI restriction overhangs are shown in bold.
Antibodies and reagents used for FCM analysis.
| Antigen | Clone | Isotype | Fluorochrome | Labeling strategy | Source of primary Ab |
|---|---|---|---|---|---|
|
| |||||
| FLAG | M2 | Mouse IgG1 | Alexa647 or BV421 | Secondary antibody | Sigma-Aldrich |
| Blimp-1* | 3H2-E8 | Mouse IgG1 | Alexa647 | Directly conjugated | Santa Cruz Biotechnology |
| IRF4* | 3E4 | Rat IgG1 | PE | Directly conjugated | Thermo Fisher Scientific |
| Pax5* | 1H9 | Rat IgG2a | BV421 | Directly conjugated | BD Biosciences |
|
| |||||
| CD49d | L25 | Mouse IgG2b | BV421 | Secondary antibody | BD Biosciences |
| CD172a | 74-22-15 | Mouse IgG1 | Alexa647 | Directly conjugated | In-house |
|
| |||||
| CD79α | HM47 | Mouse IgG1 | Alexa488 | Directly conjugated | Thermo Fisher Scientific |
| Blimp-1 | 3H2-E8 | Mouse IgG1 | Alexa647 | Directly conjugated | Santa Cruz Biotechnology |
| IRF4 | 3E4 | Rat IgG1 | PE | Directly conjugated | Thermo Fisher Scientific |
|
| |||||
| CD49d | L25 | Mouse IgG2b | BV605 | Directly conjugated | BD Biosciences |
| CD79α | HM47 | Mouse IgG1 | Alexa488 | Directly conjugated | Thermo Fisher Scientific |
| Blimp-1 | 3H2-E8 | Mouse IgG1 | Alexa647 | Directly conjugated | Santa Cruz Biotechnology |
| IRF4 | 3E4 | Rat IgG1 | PE | Directly conjugated | Thermo Fisher Scientific |
| IgG | MT424 | Mouse IgG2a | BV421 | Secondary antibody | Mabtech |
| IgM* | 5C9 | Mouse IgG1 | BV510 | Biotin-streptavidin | In-house |
| IgA* | Polyclonal | Goat | BV510 | Biotin-streptavidin | Bio-Rad |
|
| |||||
| CD49d | L25 | Mouse IgG2b | BV605 | Directly conjugated | BD Biosciences |
| SLA-DR | MSA3 | Mouse IgG2a | BV510 | Biotin-streptavidin | In-house |
| CD79α | HM47 | Mouse IgG1 | Alexa488 | Directly conjugated | Thermo Fisher Scientific |
| Blimp-1 | 3H2-E8 | Mouse IgG1 | Alexa647 | Directly conjugated | Santa Cruz Biotechnology |
| IRF4 | 3E4 | Rat IgG1 | PE | Directly conjugated | Thermo Fisher Scientific |
| Ki-67 | B56 | Mouse IgG1 | BV421 | Directly conjugated | BD Biosciences |
|
| |||||
| CD9 | VIV-3B3 | Mouse IgG1 | PE | Directly conjugated | In-house |
| CD28 | 3D11 | Mouse IgG1 | BV510 | Biotin-Streptavidin | In-house |
| CD49d | L25 | Mouse IgG2b | BV605 | Directly conjugated | BD Biosciences |
| CD79α | HM47 | Mouse IgG1 | Alexa488 | Directly conjugated | Thermo Fisher Scientific |
| Blimp-1 | 3H2-E8 | Mouse IgG1 | Alexa647 | Directly conjugated | Santa Cruz Biotechnology |
| IRF4 | 3E4 | Rat IgG1 | eFluor450 | Directly conjugated | Thermo Fisher Scientific |
|
| |||||
| CD49d | L25 | Mouse IgG2b | BV605 | Directly conjugated | BD Biosciences |
| CD79α | HM47 | Mouse IgG1 | Alexa488 | Directly conjugated | Thermo Fisher Scientific |
| Blimp-1 | 3H2-E8 | Mouse IgG1 | Alexa647 | Directly conjugated | Santa Cruz Biotechnology |
| IRF4 | 3E4 | Rat IgG1 | eFluor450 | Directly conjugated | Thermo Fisher Scientific |
| Pax5 | 1H9 | Rat IgG2a | PerCP-Cy5.5 | Directly conjugated | BioLegend |
|
| |||||
| CD21 | B-ly4 | Mouse IgG1 | BV605 | Directly conjugated | BD Biosciences |
| CD79α | HM47 | Mouse IgG1 | Alexa488 | Directly conjugated | Thermo Fisher Scientific |
| Blimp-1 | 3H2-E8 | Mouse IgG1 | Alexa647 | Directly conjugated | Santa Cruz Biotechnology |
| IRF4 | 3E4 | Rat IgG1 | PE | Directly conjugated | Thermo Fisher Scientific |
Goat anti-mouse IgG1-Alexa647, Thermo Fisher Scientific.
Rat anti-mouse IgG1-BV421, clone RMG1-1, BioLegend, San Jose, CA, USA.
Goat anti-mouse IgG2b-BV421, Jackson ImmunoResearch.
Alexa Fluor-647 Protein Labeling kit, Thermo Fisher Scientific.
Goat anti-mouse IgG2a-BV421, Jackson ImmunoResearch.
Sulfo-NHS-LC Biotin, Thermo Fisher Scientific.
Streptavidin-BV510, BioLegend.
Purchased from ATCC, Manassas, VA, USA, in-house preparation.
PE/R-Phycoerythrin Conjugation Kit, Lightning-Link®, Abcam, Cambridge, UK.
Hybridoma kindly provided by Niklas Beyersdorf (46).
*mAbs were used in different samples.
Figure 1Cross-reactivity testing of anti-mouse monoclonal antibodies on recombinant porcine proteins. HEK293T cells were transfected with expression vectors coding for porcine Blimp-1-FLAG, IRF4-FLAG, or Pax5-FLAG to test for cross-reactivity of the anti-mouse antibodies in FCM. Non-transfected HEK293T cells were used as control. Cells were stained with mAbs against mouse Blimp-1 (clone 3H2-E8, Santa Cruz), IRF4 (clone 3E4, Thermo Fisher Scientific), or Pax5 (clone 1H9, BD Biosciences), in combination with anti-FLAG specific mAbs. Quadrants indicate the frequencies of positively stained cells.
Figure 2Characterization of porcine PCs in lymphatic and non-lymphatic organs. The expression pattern of Blimp-1, IRF4, and Pax5 was analyzed by FCM in blood, spleen, mediastinal lymph node (Ln Med), mesenteric lymph node (Ln Mes), bone marrow (BM), and lung. (A) A uniform gating strategy for the analysis of PCs by FCM was used. After applying a time gate, lymphocytes were gated according to their light scatter properties (FSC-A vs. SSC-A), followed by doublet discrimination (FSC-A vs. FSC-H) and exclusion of dead cells (gating on viability-dye negative cells). The gating strategy is shown for PBMC of one representative animal and was uniformly applied to all samples. (B) Cells were further gated based on their CD79α and IRF4 expression into CD79α+IRF4dim (gray) and CD79αdim/+IRF4+ cells (red, first column). The IRF4+ population was further gated on Blimp-1+ cells (red, second column). The expression of Pax5 was analyzed in both populations (CD79α+IRF4dim in gray and Blimp-1+IRF4+ in red) and displayed in histogram overlays on the right. Data are shown for one representative animal for all organs analyzed.
Figure 3Frequencies of Ig-classes within Blimp-1+IRF4+ PCs at different anatomical locations. (A) Live lymphocytes were gated on CD79α+IRF4high cells and further into Blimp1+IRF4+ PCs (red). Gray color represents the CD79α+IRF4dim population. (B) Frequencies for IgM, IgG, and IgA expressing cells were investigated in blood, spleen, mediastinal lymph node (Ln Med), mesenteric lymph node (Ln Mes), bone marrow (BM), and lung within Blimp-1+IRF4+ cells. Pseudocolor plots of the six anatomical locations are shown for one representative animal and frequencies of positive cells are indicated in the quadrants. (C) The graph on the left shows the frequencies of Blimp-1+IRF4+ PCs within live lymphocytes of all animals and organs analyzed. The following three graphs display the frequencies of IgM+, IgG+, and IgA+ cells within Blimp-1+IRF4+ PCs (n = 6 for all organs except Ln Med with n = 5), horizontal bars in the graphs indicate respective mean values.
Figure 4Expression of Ki-67 and MHC-II on Blimp-1+IRF4+ PCs at different anatomical locations. (A) Expression of Ki-67 (left column) and MHC-II (right column) in CD79α+IRF4dim cells (gray) and Blimp-1+IRF4+ PCs (red) was investigated by FCM. Histogram overlays are shown for one representative animal for each organ. MFIs and percentages of positive cells are shown in (B) for Ki-67 and in (C) for MHC-II in Blimp-1+IRF4+ PCs (left) and CD79α+IRF4dim B cells (right) for all animals analyzed (n = 6 for all organs except Ln Med with n = 5). Respective MFIs are displayed at levels of 103 within total CD79α+IRF4dim or Blimp-1+IRF4+ cells. Dashed lines in (A) indicate gating of Ki-67 and MHC-II-positive cells; horizontal bars in (B, C) represent the respective mean values.
Figure 5Expression of CD9 and CD28 on Blimp-1+IRF4+ PCs at different anatomical locations. (A) Expression of CD9 (left column) and CD28 (right column) in CD79α+IRF4dim cells (gray) and Blimp-1+IRF4+ PCs (red) was investigated by FCM. Histogram overlays are shown for one representative animal for each organ. MFIs are shown in (B) for CD9 and in (C) for CD28 in Blimp-1+IRF4+ PCS (left) and CD79α+IRF4dim B cells (right) for all animals analyzed (n = 6 for all organs except Ln Med with n = 5). Respective MFIs are displayed at levels of 103 within total CD79α+IRF4dim or Blimp-1+IRF4+ cells; horizontal bars represent the respective mean values.
Figure 6FACS sorting of live PCs and functional analysis. (A) CD3/CD16 depleted blood-derived cells were further gated for doublet discrimination (FSC-A vs. FSC-H) and exclusion for CD172a as well as CD3+CD16+ cells remaining from the MACS sort. CD3-CD16-CD172a- cells were finally sorted based on their expression of CD49d and FSC-A properties into two populations: CD49d-/+ (blue) and CD49dhighFSC-Ahigh (red). (B) After sorting, cell populations were stained for CD79α, Blimp-1, and IRF4. Stacked histograms represent the expression of CD79α in both sorted populations as well as in the corresponding unstained controls (gray). The pseudocolor plot shows the frequency of Blimp-1+IRF4+ cells within the CD49dhigh sorted population. Percentages of Blimp-1+IRF4+ cells in the two sorted populations are summarized in the graph on the right (n = 4). (C) Two representative wells of the B-cell IgG ELISpot for the sorted populations are shown on the left. The numbers of counted spots for all animals analyzed are summarized in the graph on the left and indicated within 2 × 104 seeded cells (n = 4). The graph in the middle shows the frequencies of IgG-producing cells calculated within total Blimp-1+IRF4+ cells for the CD49dhigh-sorted population of the respective animals (n = 4). The graph on the right shows frequencies of IgG-producing cells calculated within total IgG+Blimp-1+IRF4+ cells as analyzed in parallel according to in three of the four animals. Horizontal bars represent the respective mean values.
Figure 7Expression of CD49d on Blimp-1+IRF4+ PCs at distinct anatomical locations. (A) Expression of CD49d in CD79α+IRF4dim cells (gray) and Blimp-1+IRF4+ PCs (red) was investigated by FCM. Histogram overlays are shown for one representative animal. (B) MFIs for CD49d within Blimp-1+IRF4+ PCs are shown for all animals analyzed (n = 6 for all organs except Ln Med with n = 5). Respective MFIs are displayed at levels of 103; horizontal bars represent the respective mean values.